ScholarLens Back to search
2009•Hematology Meeting Reports (formerly Haematologica Reports)Requires access

Optimizing bexarotene therapy for cutaneous T-cell lymphoma

Madeleine Duvic

Open publisher page 1 citations

Abstract

Bexarotene (Targretin® oral capsules) is the first RXR selective retinoid rexinoid, approved for all stages of cutaneous T-cell lymphoma (CTCL). Two phase II clinical trials were conducted in early and advanced patients with CTCL (Mycosis Fungoides (MF) and Sezary Syndrome (SS). The overall response rate RR was 45% at an optimal dose of 300 mg/m2/day. Higher response rates were seen in earlier patients (54%) and at higher doses 300 mg/m2/day. Hypertriglyceridemia was reported in 79% of the patients and therefore we always administer liipid lowering agents (LLA) to optimize the clinical response. Statins (inhibitors of HMG-CoA reductase) may modulate class II MHC expression and T-cell responses.

About this research paper

What this paper is about

Bexarotene (Targretin® oral capsules) is the first RXR selective retinoid rexinoid, approved for all stages of cutaneous T-cell lymphoma (CTCL). Two phase II clinical trials were conducted in early and advanced patients with CTCL (Mycosis Fungoides (MF) and Sezary Syndrome (SS). The overall response rate RR was 45% at an optimal dose of 300 mg/m2/day. Higher response rates were seen in earlier patients (54%) and at higher doses 300 mg/m2/day. Hypertriglyceridemia was reported in 79% of the patients and therefore we always administer liipid lowering agents (LLA) to optimize the clinical response. Statins (inhibitors of HMG-CoA reductase) may modulate class II MHC expression and T-cell responses.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Bexarotene (Targretin® oral capsules) is the first RXR selective retinoid rexinoid, approved for all stages of cutaneous T-cell lymphoma (CTCL). Two phase II clinical trials were conducted in early and advanced patients with CTCL (Mycosis Fungoides (MF) and Sezary Syndrome (SS). The overall response rate RR was 45% at an optimal dose of 300 mg/m2/day. Higher response rates were seen in earlier patients (54%) and at higher doses 300 mg/m2/day. Hypertriglyceridemia was reported in 79% of the patients and therefore we always administer liipid lowering agents (LLA) to optimize the clinical response. Statins (inhibitors of HMG-CoA reductase) may modulate class II MHC expression and T-cell responses.

Key concepts: Bexarotene, Mycosis fungoides, Cutaneous T-cell lymphoma, Medicine, Lymphoma, Clinical trial, Dermatology, Retinoid

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Optimizing bexarotene therapy for cutaneous T-cell lymphoma — Research Paper | ScholarLens